We previously reported that CPZ inhibits the proliferation of AML and lung adenocarcinoma cells harboring activating RTK mutations by disrupting CCV formation and altering the subcellular localization of RTKs such as FLT3-ITD and c-Kit V617F [33,34]. The gene discussed is KIT; the disease is lung adenocarcinoma.